Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
03 August 2022 - 9:30PM
Business Wire
Conference call and webcast at 8:30am ET
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patient lives by
developing and commercializing differentiated and innovative
products across a range of therapies, today announced that the
Company will release its second quarter 2022 financial results
before the open of the U.S. financial markets on Wednesday, August
10, 2022. Management will host a conference call and webcast at
8:30 a.m. Eastern Time that day to discuss the Company’s financial
and operational results.
To pre-register for the conference call please use this link:
https://ige.netroadshow.com/registration/q4inc/11152/xeris-biopharma-second-quarter-2022-financial-results-call/.
After registering, a confirmation email will be sent, including
dial-in details and a unique code for entry. The Company recommends
registering a minimum of ten minutes prior to the start of the
call. Following the conference call, a replay will be available
until Wednesday, August 24, 2022, at US:1 929 458 6194, US Toll
Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or
all other locations: +44 204 525 0658 Access Code: 562978. In
addition, a live audio of the conference call will be available as
a webcast. To join the webcast, please visit “Events” on investor
relations page of the Company’s website at www.xerispharma.com.
About Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patient lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, the first and only FDA-approved
therapy for primary periodic paralysis; and Recorlev® for the
treatment of endogenous Cushing’s syndrome. Xeris also has a
pipeline of development programs to extend the current marketed
products into important new indications and uses and bring new
products forward using its proprietary formulation technology
platforms, XeriSol™ and XeriJect™, supporting long-term product
development and commercial success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220803005159/en/
Allison Wey Senior Vice President, Investor Relations and
Corporate Communications awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024